TY - JOUR
T1 - Initial report of KSCC0803
T2 - Feasibility study of capecitabine as adjuvant chemotherapy for stage III colon cancer in Japanese patients
AU - Emi, Yasunori
AU - Kakeji, Yoshihiro
AU - Oki, Eiji
AU - Saeki, Hiroshi
AU - Ando, Koji
AU - Kitazono, Masaki
AU - Sakaguchi, Yoshihisa
AU - Morita, Masaru
AU - Samura, Hironori
AU - Ogata, Yutaka
AU - Akagi, Yoshito
AU - Natsugoe, Shoji
AU - Shirouzu, Kazuo
AU - Tokunaga, Shoji
AU - Sirzen, Florin
AU - Maehara, Yoshihiko
N1 - Funding Information:
Yoshihiko Maehara has received research funding from Chugai Pharmaceutical. All other authors declare no conflicts of interest.
PY - 2013/4
Y1 - 2013/4
N2 - Background: A prospective feasibility study was planned to clarify the proportion of compliance and adverse events in the administration of capecitabine as adjuvant chemotherapy for colon cancer in Japanese patients. Methods: We aimed initially to register 92 cases of R0 stage III colon cancer. Capecitabine (2,500 mg/m2/day) was given orally on days 1-14 every 3 weeks for 8 cycles. The proportion of treatments completed as planned was selected as the primary endpoint. Results: Ninety-seven cases were registered and treated between September 2008 and August 2009. The proportion of treatments completed in the full analysis set was 64/97 [66.0%; 95% confidence interval (CI), 55.7-75.3%] and in the per protocol set was 64/91 (70.3%; 95% CI, 59.8-79.5%). Adverse events which led to treatment discontinuation included hand-foot syndrome (HFS) (7), haematotoxicity (5) and increased hepatic damage (4). The proportions of patients with major grade 3/4 adverse events were HFS 22.7%, neutropenia 7.2%, diarrhoea 2.1%, and increased bilirubin 0.0%. Conclusions: This collaborative multi-facility study, the first of its kind in Japan, presented results of a safety confirmation experiment on capecitabine as adjuvant chemotherapy for stage III colon cancer. The results suggest that capecitabine may be administered safely to Japanese patients.
AB - Background: A prospective feasibility study was planned to clarify the proportion of compliance and adverse events in the administration of capecitabine as adjuvant chemotherapy for colon cancer in Japanese patients. Methods: We aimed initially to register 92 cases of R0 stage III colon cancer. Capecitabine (2,500 mg/m2/day) was given orally on days 1-14 every 3 weeks for 8 cycles. The proportion of treatments completed as planned was selected as the primary endpoint. Results: Ninety-seven cases were registered and treated between September 2008 and August 2009. The proportion of treatments completed in the full analysis set was 64/97 [66.0%; 95% confidence interval (CI), 55.7-75.3%] and in the per protocol set was 64/91 (70.3%; 95% CI, 59.8-79.5%). Adverse events which led to treatment discontinuation included hand-foot syndrome (HFS) (7), haematotoxicity (5) and increased hepatic damage (4). The proportions of patients with major grade 3/4 adverse events were HFS 22.7%, neutropenia 7.2%, diarrhoea 2.1%, and increased bilirubin 0.0%. Conclusions: This collaborative multi-facility study, the first of its kind in Japan, presented results of a safety confirmation experiment on capecitabine as adjuvant chemotherapy for stage III colon cancer. The results suggest that capecitabine may be administered safely to Japanese patients.
UR - http://www.scopus.com/inward/record.url?scp=84880920640&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84880920640&partnerID=8YFLogxK
U2 - 10.1007/s10147-011-0371-7
DO - 10.1007/s10147-011-0371-7
M3 - Article
C2 - 22240888
AN - SCOPUS:84880920640
SN - 1341-9625
VL - 18
SP - 254
EP - 259
JO - International Journal of Clinical Oncology
JF - International Journal of Clinical Oncology
IS - 2
ER -
